Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.74 |
| ▸ | MAPK11 | Q15759 | 8/20 | 0.74 |
| ▸ | MAPK13 | O15264 | 8/20 | 0.74 |
| ▸ | MAPK12 | P53778 | 7/20 | 0.74 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | DDR2 | Q16832 | 3/20 | 0.58 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.58 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.58 |
| ▸ | SRC | P12931 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4594410 | 0.89 | MAPK14 (0.82) | MAPK14MAPK11MAPK13MAPK12ERBB2 | |
| SCHEMBL937277 | 0.88 | MAPK14 (0.74) | MAPK14MAPK11MAPK13MAPK12ERBB2 | |
| SCHEMBL937765 | 0.88 | MAPK14 (0.67) | MAPK14MAPK11MAPK13MAPK12ERBB2 | |
| SCHEMBL5732952 | 0.88 | MAPK14 (0.78) | MAPK14MAPK11MAPK13MAPK12ERBB2 | |
| SCHEMBL5733849 | 0.85 | MAPK14 (0.75) | MAPK14MAPK11MAPK13MAPK12ERBB2 | |
| SCHEMBL4307812 | 0.85 | MAPK14 (0.80) | MAPK14MAPK11MAPK13MAPK12DDR2 | |
| SCHEMBL2083622 | 0.85 | MAPK14 (0.83) | MAPK14MAPK11MAPK13MAPK12DDR2 | |
| SCHEMBL3192951 | 0.85 | MAPK14 (0.83) | MAPK14MAPK11MAPK13MAPK12MAPT | |
| SCHEMBL4050509 | 0.84 | MAPK14 (0.90) | MAPK14MAPK11MAPK13MAPK12DDR2 | |
| SCHEMBL937570 | 0.83 | MAPK14 (0.71) | MAPK14MAPK11MAPK13MAPK12ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2324825-A1 | Aryl ureas with angiogenesis inhibiting activity | Bayer Healthcare LLC (US) | 2011-05-25 | — | — | EP | claimed |
| US-7838541-B2 | Aryl ureas with angiogenesis inhibiting activity | BAYER HEALTHCARE, LLC (US) | 2010-11-23 | — | — | US | claimed |
| EP-1056725-B1 | INHIBITION OF RAF KINASE USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS | BAYER PHARMACEUTICALS CORP (US) | 2006-06-07 | — | — | EP | claimed |
| US-10653684-B2 | Aryl ureas with angiogenisis inhibiting activity | BAYER HEALTHCARE LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-20180296541-A9 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2018-10-18 | — | — | US | disclosed |
| US-20160015697-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2016-01-21 | — | — | US | disclosed |
| US-8618141-B2 | Aryl ureas with angiogenesis inhibiting activity | BAYER HEALTHCARE LLC (US) | 2013-12-31 | — | — | US | disclosed |
| US-20120289552-A1 | ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-8242147-B2 | Aryl ureas with angiogenisis inhibiting activity | BAYER HEALTHCARE LLC (US) | 2012-08-14 | — | — | US | disclosed |
| EP-2324825-A1 | Aryl ureas with angiogenesis inhibiting activity | Bayer Healthcare LLC (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20110015195-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | DUMAS JACQUES | 2011-01-20 | — | — | US | disclosed |
| US-7838541-B2 | Aryl ureas with angiogenesis inhibiting activity | BAYER HEALTHCARE, LLC (US) | 2010-11-23 | — | — | US | disclosed |
| US-20080227828-A1 | Aryl Ureas With Angiogenisis Inhibiting Activity | BAYER HEALTHCARE LLC | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180296541-A9 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | FLT1, FLT4, KDR | MAPK14 445/4885MAPK11 124/4885MAPK13 126/4885 |
| US-10653684-B2 | Aryl ureas with angiogenisis inhibiting activity | FLT1, FLT4, KDR | MAPK14 445/4885MAPK11 124/4885MAPK13 126/4885 |
| US-20110015195-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | FLT1, FLT4, KDR | MAPK14 445/4885MAPK11 124/4885MAPK13 126/4885 |
| US-20080227828-A1 | Aryl Ureas With Angiogenisis Inhibiting Activity | FLT1, FLT4, KDR | MAPK14 445/4885MAPK11 124/4885MAPK13 126/4885 |
| US-20120289552-A1 | ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY | FLT4, FLT1, KDR | MAPK14 380/4885MAPK11 246/4885MAPK13 157/4885 |
| US-20160015697-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | FLT1, FLT4, KDR | MAPK14 445/4885MAPK11 124/4885MAPK13 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.